[1]
Kainuma S, Taniguchi K, Daimon T, et al. Mitral valve repair for medically refractory functional mitral regurgitation in patients with end-stage renal disease and advanced heart failure. Circulation 2012; 126(11)(Suppl. 1): S205-13.
[2]
Wan B, Rahnavardi M, Tian DH, et al. A meta-analysis of MitraClip system versus surgery for treatment of severe mitral regurgitation. Ann Cardiothorac Surg 2013; 2(6): 683.
[3]
Feldman T, Foster E, Glower DD, et al. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med 2011; 364(15): 1395-406.
[4]
Sürder D, Pedrazzini G, Gaemperli O, et al. Predictors for efficacy of percutaneous mitral valve repair using the MitraClip system: The results of the MitraSwiss registry. Heart 2013; 99(14): 1034-40.
[5]
Toggweiler S, Zuber M, Sürder D, et al. Two-year outcomes after percutaneous mitral valve repair with the MitraClip system: Durability of the procedure and predictors of outcome. Open Heart 2014; 1(1): e000056.
[6]
Ohno Y, Attizzani GF, Capodanno D, et al. Association of tricuspid regurgitation with clinical and echocardiographic outcomes after percutaneous mitral valve repair with the MitraClip System: 30-day and 12-month follow-up from the GRASP Registry. Eur Heart J Cardiovasc Imaging 2014; 15(11): 1246-55.
[7]
Paranskaya L, D’ancona G, Bozdag‐Turan I, et al. Residual mitral valve regurgitation after percutaneous mitral valve repair with the mitraclip® system is a risk factor for adverse one‐year outcome. Catheter Cardiovasc Interv 2013; 81(4): 609-17.
[8]
Kahn MR, Robbins MJ, Kim MC, Fuster V. Management of cardiovascular disease in patients with kidney disease. Nat Rev Cardiol 2013; 10(5): 261.
[9]
Gaasch WH, Zile MR. Left ventricular function after surgical correction of chronic mitral regurgitation. Eur Heart J 1991; 12(Suppl. B): 48-51.
[10]
Shah PM, Adelman AG, Wigle ED, et al. The natural and unnatural history of hypertrophic obstructive cardiomyopathy: A multicenter study. Circ Res 1974; 35(2): II-179.
[11]
Zile MR, Gaasch WH, Levine HJ. Left ventricular stress-dimension-shortening relations before and after correction of chronic aortic and mitral regurgitation. Am J Cardiol 1985; 56(1): 99-105.
[12]
Corin WJ, Monrad ES, Murakami T, Nonogi H, Hess OM, Krayenbuehl HP. The relationship of afterload to ejection performance in chronic mitral regurgitation. Circulation 1987; 76(1): 59-67.
[13]
Rassaf T, Balzer J, Rammos C, et al. Influence of percutaneous mitral valve repair using the MitraClip® system on renal function in patients with severe mitral regurgitation. Catheter Cardiovasc Interv 2015; 85(5): 899-903.
[14]
Parfrey PS, Harriett JD, Griffiths SM, et al. The clinical course of left ventricular hypertrophy in dialysis patients. Nephron 1990; 55(2): 114-20.
[15]
Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Thorac Cardiovasc Surg 2014; 148(1): e1-e32.
[16]
Vahanian A. Task Force on the Management of Valvular Hearth Disease of the European Society of Cardiology: ESC Committee for Practice Guidelines. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J 2007; 28: 230-68.
[17]
Feldman T, Wasserman HS, Herrmann HC, et al. Percutaneous mitral valve repair using the edge-to-edge technique: Six-month results of the EVEREST Phase I Clinical Trial. J Am Coll Cardiol 2005; 46(11): 2134-40.
[18]
Wang A, Sangli C, Lim S, et al. Evaluation of renal function before and after percutaneous mitral valve repair. Circ Cardiovasc Interv 2015; 8(1): e001349.
[19]
Kaneko H, Neuss M, Schau T, Weissenborn J, Butter C. Interaction between renal function and percutaneous edge-to-edge mitral valve repair using MitraClip. J Cardiol 2017; 69(2): 476-82.
[20]
Kubo S, Nakamura M, Shiota T, et al. Impact of forward stroke volume response on clinical and structural outcomes after percutaneous mitral valve repair with mitraclip. Circ Cardiovasc Interv 2017; 10(7): e004909.
[21]
Braunwald E. Mitral regurgitation: physiologic, clinical and surgical considerations. N Engl J Med 1969; 281(8): 425-33.
[22]
Damman K, Navis G, Smilde TD, et al. Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction. Eur J Heart Fail 2007; 9(9): 872-8.
[23]
Biner S, Siegel RJ, Feldman T, et al. Acute effect of percutaneous MitraClip therapy in patients with haemodynamic decompensation. Eur J Heart Fail 2012; 14(8): 939-45.
[24]
Siegel RJ, Biner S, Rafique AM, et al. The acute hemodynamic effects of MitraClip therapy. J Am Coll Cardiol 2011; 57(16): 1658-65.
[25]
Hoar PF, Mookerjee A, Stone JG, Wicks AE, Malm JR, Mirsky MB. Acute hemodynamic alterations after mitral valve replacement with the glutaraldehyde-treated porcine heterograft prosthesis. Ann Thorac Surg 1980; 29(5): 434-9.
[26]
Landoni G, Zangrillo A, Franco A, et al. Long-term outcome of patients who require renal replacement therapy after cardiac surgery. Eur J Anaesthesiol 2006; 23(1): 17-22.
[27]
Tang P, Onaitis M, Desai B, et al. Minithoracotomy versus sternotomy for mitral surgery in patients with chronic renal impairment: a propensity-matched study. Innovations (Phila) 2013; 8(5): 325-31.
[28]
Loef BG, Epema AH, Smilde TD, et al. Immediate postoperative renal function deterioration in cardiac surgical patients predicts in-hospital mortality and long-term survival. J Am Soc Nephrol 2005; 16(1): 195-200.
[29]
Foster E, Kwan D, Feldman T, et al. Percutaneous mitral valve repair in the initial EVEREST cohort: Evidence of reverse left ventricular remodeling. Circ Cardiovasc Imaging 2013; 6(4): 522-30.
[30]
Grayburn PA, Foster E, Sangli C, et al. The relationship between the magnitude of reduction in mitral regurgitation severity and left ventricular and left atrial reverse remodeling after mitraclip® therapy. Circulation 2013; 128(15): 1667-74.
[31]
Suri RM, Schaff HV, Dearani JA, et al. Recovery of left ventricular function after surgical correction of mitral regurgitation caused by leaflet prolapse. J Thorac Cardiovasc Surg 2009; 137(5): 1071-6.
[32]
Husain-Syed F, McCullough PA, Birk HW, et al. Cardio-pulmonary-renal interactions. J Am Coll Cardiol 2015; 65(22): 2433-48.
[33]
Vitarelli A, Mangieri E, Capotosto L, et al. Assessment of biventricular function by three-dimensional speckle-tracking echocardiography in secondary mitral regurgitation after repair with the MitraClip system. J Am Soc Echocardiogr 2015; 28(9): 1070-82.
[34]
Moesgaard SG, Klostergaard C, Zois NE, et al. Flow‐mediated vasodilation measurements in Cavalier King Charles Spaniels with increasing severity of myxomatous mitral valve disease. J Vet Intern Med 2012; 26(1): 61-8.
[35]
Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000; 87(10): 840-4.
[36]
Sutton TA, Fisher CJ, Molitoris BA. Microvascular endothelial injury and dysfunction during ischemic acute renal failure. Kidney Int 2002; 62(5): 1539-49.
[37]
Rammos C, Zeus T, Balzer J, et al. Percutaneous mitral valve repair in mitral regurgitation reduces cell-free hemoglobin and improves endothelial function. PLoS One 2016; 11(3): e0151203.
[38]
Körber MI, Scherner M, Kuhr K, et al. Acute kidney injury following percutaneous edge-to-edge vs. minimally invasive surgical mitral valve repair: Incidence, predictors and prognostic value. EuroIntervention 2018; 13(14): 1645-51.
[39]
Chang CH, Lee CC, Chen SW, et al. Predicting acute kidney injury following mitral valve repair. Int J Med Sci 2016; 13(1): 19.
[40]
Ram P, Mezue K, Pressman G, Rangaswami J. Acute kidney injury post–transcatheter aortic valve replacement. Clin Cardiol 2017; 40(12): 1357-62.
[41]
Spieker M, Hellhammer K, Katsianos S, et al. Effect of acute kidney injury following percutaneous mitral valve repair on outcome. Am J Cardiol 2018; 122(2): 316-22.
[42]
Kooiman J, Seth M, Nallamothu BK, Heung M, Humes D, Gurm HS. Association between acute kidney injury and in-hospital mortality in patients undergoing percutaneous coronary interventions. Circ Cardiovasc Interv 2015; 8(6): e002212.
[43]
Lio A, Miceli A, Varone E, et al. Mitral valve repair versus replacement in patients with ischaemic mitral regurgitation and depressed ejection fraction: Risk factors for early and mid-term mortality. Interact Cardiovasc Thorac Surg 2014; 19(1): 64-9.
[44]
Udesh R, Mehta A, Gleason TG, Wechsler L, Thirumala PD. Perioperative strokes and early outcomes in mitral valve surgery: a nationwide analysis. J Cardiothorac Vasc Anesth 2017; 31(2): 529-36.
[45]
Ledwoch J, Bertog S, Wunderlich N, et al. Predictors for prolonged hospital stay after transcatheter mitral valve repair with the MitraClip®. Catheter Cardiovasc Interv 2014; 84(4): 599-605.
[46]
Damman K, Valente MA, Voors AA, O’connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: An updated meta-analysis. Eur Heart J 2013; 35(7): 455-69.
[47]
Damman K, Voors AA, Navis G, van Veldhuisen DJ, Hillege HL. The cardiorenal syndrome in heart failure. Prog Cardiovasc Dis 2011; 54(2): 144-53.
[48]
Cooper WA, O’brien SM, Thourani VH, et al. Impact of renal dysfunction on outcomes of coronary artery bypass surgery: Results from the Society of Thoracic Surgeons National Adult Cardiac Database. Circulation 2006; 113(8): 1063-70.
[49]
Gupta T, Goel K, Kolte D, et al. Association of chronic kidney disease with in-hospital outcomes of transcatheter aortic valve replacement. JACC Cardiovasc Interv 2017; 10(20): 2050-60.
[50]
Lio A, Miceli A, Varone E, et al. Mitral valve repair versus replacement in patients with ischaemic mitral regurgitation and depressed ejection fraction: Risk factors for early and mid-term mortality. Interact Cardiovasc Thorac Surg 2014; 19(1): 64-9.
[51]
Udesh R, Mehta A, Gleason TG, Wechsler L, Thirumala PD. Perioperative strokes and early outcomes in mitral valve surgery: A nationwide analysis. J Cardiothorac Vasc Anesth 2017; 31(2): 529-36.
[52]
Ledwoch J, Bertog S, Wunderlich N, et al. Predictors for prolonged hospital stay after transcatheter mitral valve repair with the MitraClip®. Catheter Cardiovasc Interv 2014; 84(4): 599-605.
[53]
Estévez-Loureiro R, Settergren M, Pighi M, et al. Effect of advanced chronic kidney disease in clinical and echocardiographic outcomes of patients treated with MitraClip system. Int J Cardiol 2015; 198: 75-80.
[54]
Shah B, Vemulapalli S, Manandhar P, et al. Outcomes after transcatheter mitral valve repair in patients with chronic kidney disease: An analysis of 5,241 patients in the United States. J Am Coll Cardiol 2018; 71(11): A1980.
[55]
Dumonteil N, Van Der Boon RM, Tchetche D, et al. Impact of preoperative chronic kidney disease on short-and long-term outcomes after transcatheter aortic valve implantation: A Pooled-RotterdAm-Milano-Toulouse In Collaboration Plus (PRAGMATIC-Plus) initiative substudy. Am Heart J 2013; 165(5): 752-60.
[56]
Yamamoto M, Hayashida K, Mouillet G, et al. Prognostic value of chronic kidney disease after transcatheter aortic valve implantation. J Am Coll Cardiol 2013; 62(10): 869-77.
[57]
Neuss M, Schau T, Schoepp M, et al. Patient selection criteria and midterm clinical outcome for MitraClip therapy in patients with severe mitral regurgitation and severe congestive heart failure. Eur J Heart Fail 2013; 15(7): 786-95.
Download PDF Flyer